Next compound en route

SPK004377 was predicted to have good binding and functional profiles for receptors involved Central Nervous System diseases. Based on this profile, it was selected from a library of 15,000+ designs for synthesis. This compound is being forwarded to one of our CRO partners for verification tests that Q-MAP™ will use to iteratively improve its molecule designs. Bon voyage, SPK004377!